Investors Buy Shares of Johnson & Johnson (JNJ) on Weakness

Investors purchased shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading hours on Monday. $208.84 million flowed into the stock on the tick-up and $155.15 million flowed out of the stock on the tick-down, for a money net flow of $53.69 million into the stock. Of all stocks tracked, Johnson & Johnson had the 11th highest net in-flow for the day. Johnson & Johnson traded down ($1.78) for the day and closed at $140.00

A number of brokerages have commented on JNJ. Credit Suisse Group reiterated a “buy” rating on shares of Johnson & Johnson in a report on Friday, August 4th. Piper Jaffray Companies restated a “hold” rating and set a $120.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 4th. Vetr lowered Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price target on the stock. in a research note on Monday, September 18th. Alembic Global Advisors lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research report on Friday, July 21st. Finally, Stifel Nicolaus upped their target price on Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a research report on Wednesday, October 18th. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $143.70.

The firm has a 50 day moving average of $135.68 and a 200 day moving average of $131.64. The firm has a market cap of $376.54 billion, a price-to-earnings ratio of 24.40 and a beta of 0.78.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. The firm had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a return on equity of 27.68% and a net margin of 21.28%. Johnson & Johnson’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.68 earnings per share. On average, equities research analysts forecast that Johnson & Johnson will post $7.28 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.41%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s dividend payout ratio is currently 58.33%.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Harding Loevner LP acquired a new stake in Johnson & Johnson during the second quarter valued at approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its stake in Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after buying an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. raised its stake in Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after buying an additional 5 shares in the last quarter. IHT Wealth Management LLC raised its stake in Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after buying an additional 3,467 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc acquired a new stake in Johnson & Johnson during the second quarter valued at approximately $124,000. Hedge funds and other institutional investors own 66.06% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://sportsperspectives.com/2017/11/01/investors-buy-shares-of-johnson-johnson-jnj-on-weakness.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply